Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cocrystal Pharma, Inc. Director's Dealing 2014

Dec 17, 2014

35066_dirs_2014-12-17_60073204-e4bd-40b5-98ae-0e7484e46b63.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2014-12-15

Reporting Person: FROST PHILLIP MD ET AL (N/A)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-12-15 Common Stock P 6127 $0.4250 Acquired 12348852 Indirect
2014-12-15 Common Stock P 8873 $0.43 Acquired 12357725 Indirect
2014-12-15 Common Stock P 10000 $0.4350 Acquired 12367725 Indirect

Footnotes

F1: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.